Now showing items 1-20 of 20

    • Antiretroviral therapy : challenges and options in South Africa. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Baxter, Cheryl. (Elsevier., 2003-11-01)
      No abstract available.
    • Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. 

      Sibeko, Sengeziwe.; Baxter, Cheryl.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Yende Zuma, Nonhlanhla. (Lippincott Williams & Wilkins., 2011)
      OBJECTIVE: Women who become pregnant during the conduct of biomedical human immunodeficiency virus prevention trials are taken off the study product for safety reasons. High pregnancy rates can compromise statistical ...
    • A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. 

      Gengiah, Tanuja N.; Baxter, Cheryl.; Mansoor, Leila E.; Kharsany, Ayesha B. M.; Abdool Karim, Salim Safurdeen. (Informa Healthcare., 2011)
      Introduction: More than a million people acquire HIV infection annually. Pre-exposure prophylaxis (PrEP) using antiretrovirals is currently being investigated for HIV prevention. Oral and topical formulations of tenofovir ...
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Frohlich, Janet A.; Grobler, Anna Christina.; Baxter, Cheryl.; Mansoor, Leila E.; Kharsany, Ayesha B. M.; Sibeko, Sengeziwe.; Mlisana, Koleka.; Omar, Zaheen.; Gengiah, Tanuja N.; Maarschalk, Silvia.; Arulappan, Natasha.; Mlotshwa, Mukelisiwe.; Morris, Lynn.; Taylor, Douglas. (American Association for the Advancement of Science., 2010-09)
      The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the ...
    • Global epidemiology of HIV-AIDS. 

      Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Gouws, Eleanor.; Baxter, Cheryl. (WB Saunders., 2007-03-01)
      HIV, the cause of AIDS, has in the 25 years since its discovery spread rapidly to every region in the world [1]. To date, more than 65 million people have been infected with HIV and about 25 million people have died ...
    • HIV vaccines and immunity. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Allergy Society of South Africa., 2003-06)
      No abstract available.
    • Integration of antiretroviral therapy with tuberculosis treatment. 

      Abdool Karim, Salim Safurdeen.; Naidoo, Kogieleum.; Grobler, Anna Christina.; Padayatchi, Nesri.; Baxter, Cheryl.; Gray, Andrew L.; Gengiah, Tanuja N.; Gengiah, Santhanalakshmi.; Naidoo, Anushka.; Jithoo, Niraksha.; Nair, Gonasagrie.; El-Sadr, Wafaa.; Friedland, Gerald H.; Abdool Karim, Quarraisha. (Massachusetts Medical Society., 2011-10-20)
      Background. We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains ...
    • Microbicides & their implications in HIV prevention. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (MedKnow Publications., 2010-12)
      No abstract available.
    • Overview of microbicides for the prevention of human immunodeficiency virus. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Elsevier., 2012)
      Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four ...
    • Preventing HIV infection in women: A global health imperative. 

      Abdool Karim, Quarraisha.; Sibeko, Sengeziwe.; Baxter, Cheryl. (Oxford University Press on behalf of University of Chicago Press., 2010-05-15)
      Women account for approximately one-half of all human immunodeficiency virus (HIV) infections worldwide. Sexual transmission is the dominant mode of HIV transmission to women, and there is a concomitant associated epidemic ...
    • PRO 2000: next steps for microbicide development. 

      Abdool Karim, Salim Safurdeen.; Baxter, Cheryl. (Future Medicine., 2009)
      No abstract available.
    • Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. 

      Abdool Karim, Quarraisha.; Kharsany, Ayesha B. M.; Frohlich, Janet A.; Baxter, Cheryl.; Yende Zuma, Nonhlanhla.; Mansoor, Leila E.; Mlisana, Koleka.; Maarschalk, Silvia.; Arulappan, Natasha.; Grobler, Anna Christina.; Sibeko, Sengeziwe.; Omar, Zaheen.; Gengiah, Tanuja N.; Mlotshwa, Mukelisiwe.; Samsunder, Natasha.; Abdool Karim, Salim Safurdeen. (Biomed Central, 2011-03-07)
      Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap ...
    • Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. 

      Sokal, David C.; Abdool Karim, Quarraisha.; Sibeko, Sengeziwe.; Yende Zuma, Nonhlanhla.; Mansoor, Leila E.; Baxter, Cheryl.; Grobler, Anna Christina.; Frohlich, Janet A.; Kharsany, Ayesha B. M.; Miya, Nomsa.; Mlisana, Koleka.; Maarschalk, Silvia.; Abdool Karim, Salim Safurdeen. (International Medical Press., 2013)
      Background: Tenofovir gel, used vaginally before and after coitus, reduced women’s acquisition of HIV by 39%. This is a safety assessment of tenofovir gel, including renal, bone, gastrointestinal, genital and haematological ...
    • The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. 

      Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Baxter, Cheryl.; Friedland, Gerald H.; Gengiah, Tanuja N.; Gray, Andrew L.; Grobler, Anna Christina.; Naidoo, Kogieleum.; Padayatchi, Nesri.; El-Sadr, Wafaa. (Health and Medical Publications Group., 2010-12)
      Boulle et al.(1) queried whether a clinical trial was needed to provide the evidence for the mortality benefits of antiretroviral therapy (ART) initiation during tuberculosis (TB) treatment. While several experts, including ...
    • Strengthening HIV services for pregnant women: an opportunity to reduce maternal mortality rates in Southern Africa/Sub-Saharan Africa. 

      Moodley, Jagidesa.; Pattinson, R. C.; Baxter, Cheryl.; Sibeko, Sengeziwe.; Abdool Karim, Quarraisha. (Wiley-Blackwell., 2011-01)
      Reliable data from South Africa emanating from WHO recommendations for the Safe Motherhood programme underscores HIV/AIDS as the most common cause of maternal deaths. The strengthening of HIV services for pregnant women ...
    • Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. 

      Mlisana, Koleka.; Naicker, Nivashnee.; Werner, Lise.; Roberts, Lindi.; Van Loggerenberg, Francois.; Baxter, Cheryl.; Passmore, Jo-Ann.; Grobler, Anna Christina.; Sturm, A. Willem.; Williamson, Carolyn.; Ronacher, Katharina.; Walzl, Gerjard.; Abdool Karim, Salim Safurdeen. (Oxford University Press., 2012-07-01)
      Background. Diagnosis and treatment of sexually transmitted infections (STIs) is a public health priority, particularly in regions where the incidence of human immunodeficiency virus (HIV) infection is high. In most ...
    • Timing of initiation of antiretroviral drugs during tuberculosis therapy. 

      Abdool Karim, Salim Safurdeen.; Naidoo, Kogieleum.; Grobler, Anna Christina.; Padayatchi, Nesri.; Baxter, Cheryl.; Gray, Andrew L.; Gengiah, Tanuja N.; Nair, Gonasagrie.; Bamber, Sheila.; Singh, Aarthi.; Khan, Munira.; Pienaar, Jacqueline C.; El-Sadr, Wafaa.; Friedland, Gerald H.; Abdool Karim, Quarraisha. (Massachusetts Medical Society., 2010)
      Background. The rates of death are high among patients with coinfection with tuberculosis and the human immunodeficiency virus (HIV). The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis ...
    • Topical microbicides - What's new? 

      Abdool Karim, Quarraisha.; Baxter, Cheryl.; Abdool Karim, Salim Safurdeen. (Lippincott Williams & Wilkins., 2013-07-01)
      Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...
    • Utilizing nucleic acid amplification to identify acute HIV infection. 

      Abdool Karim, Salim Safurdeen.; Mlisana, Koleka.; Kharsany, Ayesha B. M.; Williamson, Carolyn.; Baxter, Cheryl.; Abdool Karim, Quarraisha. (Lippincott Williams & Wilkins., 2007-03-12)
      No abstract available.
    • When to start antiretroviral therapy during tuberculosis treatment? 

      Naidoo, Kogieleum.; Baxter, Cheryl.; Abdool Karim, Salim Safurdeen. (Lippincott Williams & Wilkins., 2013-02)
      Purpose of review. Effective treatment exists for tuberculosis (TB) and for HIV, but treating both diseases simultaneously presents several challenges. This review assesses the evidence for the timing of antiretroviral ...